ANGPTL3 and homozygous familial hypercholesterolemia: Notably, the ANGPTL3 monoclonal antibody evinacumab has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of homozygous familial hypercholesterolemia (HoFH), further underscoring the considerable clinical potential of ANGPTL3 as a therapeutic target (13).